Rainbow Children's Medicare Limited
Preview the depth — unlock the full forensic study.
You're reading the free Overview. The full Landscape study, the Lenses, governance and quality scans unlock with Pro — across 5,000 Indian companies.
Briefing
Rainbow Children's Medicare Limited — the brief
Forensic posture: Material flags. The auditor gave a clean bill of health, but related-party disclosures reveal a troubling pattern: the departing COO collected ₹69.15 Cr in sudden pay hikes, the chairman's family extracted ₹132.71 Cr in dividends, and a subsidiary still owes ₹2 Cr in unpaid advances—offset only by routine ₹265 Cr in tax and litigation contingencies (1.8% of net worth) that pose minimal risk.
Auditor’s report (CARO 2020)
Auditor’s assessment Clean. Auditor: S.R. Batliboi & Associates LLP. Fiscal year FY24-25.
Related-party transactions
Assessment Concerning. Disclosed volume of ₹413 Cr across 24 related parties. Fiscal year FY25.
- Significant remuneration paid to Chief Operating Officer: Mr. Sanjeev Sukumaran (Chief Operating Officer, resigned 30 October 2024) received ₹69.15 million in remuneration including perquisites during the year, representing a substantial increase from prior year compensation of ₹23.19 million.
- Substantial rent paid to related party entity: The Company paid ₹50.80 million in rental expenditure to Unimed Healthcare Private Limited (an entity where a KMP relative is a member), with an outstanding rent payable of ₹4.90 million as of year-end.
- Unsecured inter-corporate deposit remains outstanding: An inter-corporate deposit of ₹2.00 million has been outstanding with Rosewalk Healthcare Private Limited (a subsidiary) since at least FY2024, with accumulated interest of ₹0.26 million, indicating prolonged non-repayment of this advance.
- Large dividend distribution to promoter and promoter family: Dr. Ramesh Kancharla (Chairman and Managing Director) received ₹94.48 million in dividend, and his family members including Dr. Dinesh Kumar Chirla (₹19.90 Mn) and Dr. Adarsh Kancharla (₹18.33 Mn) received substantial dividends, totaling ₹1
Contingent liabilities
Assessment Routine. Total disclosed: ₹265 Cr (1.8% of net worth). Fiscal year FY24-25.
Corporate governance
Board of 7 directors, 57% independent. Chair: Dr. Ramesh Kancharla. Chair and CEO roles are combined. Statutory auditor: Not explicitly disclosed in excerpt. Fiscal year FY24-25.
“Mr. Sanjeev Sukumaran (including perquisites) 69.15 23.19”
What retail misses·The related-party transactions reveal internal governance stress (sudden executive pay surge, unpaid subsidiary advances, and unusually large family dividend distributions) that aren't visible in headline earnings or auditor opinion—the filings show what the auditor didn't flag but what the related-party ledger does disclose.
Strengths noted in disclosures: Earnings quality composite score of 84 (Excellent) with cash flow matching profit and top-decile profitability metrics—operations are fundamentally sound. · Contingent liabilities of ₹265 Cr represent only 1.8% of net worth, all minor-severity items (no disputed amounts of material size); tax and litigation claims are routine healthcare sector exposure. · Academic bankruptcy risk model (Altman Z-Score 9.24) places the company in Safe zone with low distress probability based on profitability and leverage.
Forensic signal
From the company's own filingsWeak: Valuation · Yield